September 2017 tender notification

Tender Closed

PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2015/16 Invitation to Tender, dated 6 November 2015 and the 2016/17 Invitation to Tender, dated 3 November 2016.

Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change.  More information and NOPC forms can be found on our website(external link).

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand  (http://www.pgnz.org.nz/about-us-1/pharmacode(external link)) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (http://www.nzulm.org.nz/sponsors(external link)). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.

2015/16 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2019

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

 The decisions were as follows:

Salbutamol

Oral liq 400 mcg per ml, 150 ml bottle

$2.06

$2.95

Salapin (AFT)

1 March 2018

N/A

1 August 2018

Ventolin (GSK)

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole Supply Brand
(Supplier)

Date of listing/
subsidy change
for tender
winning brand

Date of reference
pricing of other
listed brands

Sole Subsidised Supply date
(and delisting of other listed
brands)

Brand (Supplier) affected by reference pricing and
delisting

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Salbutamol

Oral liq 400 mcg per ml, 150 ml bottle

$2.06

$2.95

Salapin (AFT)

1%

1 March 2018

1 May 2018

Ventolin (GSK)

Chemical name

Presentation;
Pack size and type

Current
pack price

New 
pack price

Hospital Supply Brand 
(Supplier)

DV limit

Listing date

Hospital Supply Status date

Brand (Supplier) affected
delisting 

2016/17 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2020

Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to listed pharmaceuticals where no other brand is listed.

 The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole supply brand
(Supplier)

Date of subsidy change

Sole Subsidised Supply date

Levodopa with carbidopa

Tab 250 mg with carbidopa 25 mg,
100 tablets, bottle pack

$40.00

$32.67

Sinemet
(MSD)

1 December 2017

1 March 2018

Levodopa with carbidopa

Tab long-acting 200 mg with carbidopa 50 mg,100 tablets, bottle pack

$47.50

$37.15

Sinemet CR
(MSD)

1 December 2017

1 March 2018

Losartan potassium with
hydrochlorothiazide*

Tab 50 mg with hydrochlorothiazide 12.5 mg, 30 tablets, blister pack

$2.18

$1.88

Arrow-Losartan & Hydrochlorothiazide
(Actavis)

1 April 2018

1 July 2018

* These products will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b) (II) of the 2016/17 Invitation To Tender

2. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

 The decisions were as follows:

Chemical name

Presentation;
Pack size and type

Current
pack price

New
pack price

Sole Supply Brand
(Supplier)

Date of listing/
subsidy change
for tender
winning brand

Date of reference
pricing of other
listed brands

Sole Subsidised Supply date
(and delisting of other listed
brands)

Brand (Supplier) affected by reference pricing and
delisting

Ciprofloxacin

Eye drops 0.3%,5 ml bottle OP

$12.43

$9.99

Ciprofloxacin Teva
(Actavis)

1 April 2018

1 June 2018

1 September 2018

Ciloxan (Alcon)

Levodopa with carbidopa

Tab 100 mg with carbidopa 25 mg, 100 tablets, bottle pack

$20.00

$17.97

Sinemet
(MSD)

1 December 2017

1 February 2018

1 May 2018

Kinson (Mylan)

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

3. Tenders awarded to listed pharmaceuticals where no other brand is listed.

The decisions were as follows:

Chemical name Presentation;
Pack size and type
Current
pack price
New
pack price
Hospital Supply Brand
(Supplier)
DV Limit Listing date Hospital Supply Status date
Levodopa with carbidopa** Tab 250 mg with carbidopa 25 mg, 100 tablets,
bottle pack
$40.00 $32.67 Sinemet (MSD) 1% 1 December 2017 1 February 2018
Levodopa with carbidopa Tab long-acting 200 mg with carbidopa 50 mg,100 tablets, bottle pack $47.50 $37.15 Sinemet CR
(MSD)
1% 1 December 2017 1 February 2018
Losartan potassium with hydrochlorothiazide* Tab 50 mg with hydrochlorothiazide 12.5 mg, 30 tablets, blister pack $2.18 $1.88 Arrow-Losartan & Hydrochlorothiazide
(Actavis)
1% 1 April 2018 1 June 2018
* These products will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b) (II) of the 2016/17 Invitation To Tender
** Please note that the example brand ’Sindopa’ will be delisted from Section H of the Pharmaceutical Schedule from 1 February 2018

4. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

The decisions were as follows:

Chemical name Presentation;
Pack size and type
Current
pack price
New
pack price
Hospital Supply Brand
(Supplier)
DV Limit Listing date Hospital Supply Status date Brand (Supplier) affected by delisting
Ciprofloxacin Eye drops 0.3%,5 ml bottle $12.43 $9.99 Ciprofloxacin Teva
(Actavis)
1% 1 April 2018 1 June 2018 Ciloxan (Alcon)
Levodopa with carbidopa Tab 100 mg with carbidopa 25 mg, 100 tablets, bottle pack $20.00 $17.97 Sinemet
(MSD)
1% 1 December 2017 1 February 2018 Kinson (Mylan)

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

* As part of a released publication of the September Tender Notification on September 29th, 2017, two items were incorrectly identified as declined; pregnancy test- HCG urine -  Dipstick and pregnancy test – HCG urine – Midstream, included in the 2016/17 Invitation to Tender. Please note, these tender lines remain unresolved and under evaluation by PHARMAC. 

PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:

  • the 2015/16 Invitation to Tender, dated 6 November 2015, and
  • the 2016/17 Invitation to Tender, dated 3 November 2016.

2015/16 Invitation to Tender

Chemical name

Line item

Cilazapril

Tab 0.5 mg – 1 mg

Clonazepam

Tab 500 mcg

Clonazepam

Tab 2 mg

2016/17 Invitation to Tender

Chemical name

Line item

Ciprofloxacin (current access)

Eye drops 0.3%

Colestimethate

Inj 150 mg

Nitrofurantoin

Tab modified-release 100 mg

Ribavirin

Tab 200 mg

Ribavirin

Tab 400 mg

Ribavirin

Tab 600 mg

For products included in the 2015/16 and 2016/17 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. 

If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.